Bioinvent: Difference between revisions

Content deleted Content added

Inline

Revision as of 14:30, 27 August 2019

BioInvent International is a Swedish research, pharmaceutical and life science company with focus on clinical development of antibody drugs for immunotherapy against cancer.^[1] The company was founded in 1983 by Carl Borrebaeck [sv] and is listed on the Stockholm Stock Exchange since 2001. The company's partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. Martin Welschof has been CEO since 2018.^[2]^[3]^[4]^[5]^[6]^[7]

References

^ Maria Phillips, "Bioinvent rasar efter emissionsbesked", Dagens industri, 25 February 2019 (in Swedish).
^ "BioInvent rekryterar Martin Welschof som ny vd" (press release), Cision, 12 April 2018 (in Swedish).
^ "BioInvent International", Avanza Bank, retrieved 19 June 2019 (in Swedish).
^ "Technology", Bioinvent, retrieved 19 June 2019.
^ Kajsa-Stina Kalin, "Bioinvent var pionjärer i parken" Sydsvenskan, 4 October 2015 (in Swedish).
^ Maria Lindh, "Forskningen som ledde till miljardavtalet", LUM., Lund University, 11 September 2015 (in Swedish).
^ "Bioinvent i nytt cancer–samarbete", Dagens Nyheter, 4 January 2012 (in Swedish; subscription required).

External links

Official website

[1] Maria Phillips, "Bioinvent rasar efter emissionsbesked", Dagens industri, 25 February 2019 (in Swedish).

[2] "BioInvent rekryterar Martin Welschof som ny vd" (press release), Cision, 12 April 2018 (in Swedish).

[3] "BioInvent International", Avanza Bank, retrieved 19 June 2019 (in Swedish).

[4] "Technology", Bioinvent, retrieved 19 June 2019.

[5] Kajsa-Stina Kalin, "Bioinvent var pionjärer i parken" Sydsvenskan, 4 October 2015 (in Swedish).

[6] Maria Lindh, "Forskningen som ledde till miljardavtalet", LUM., Lund University, 11 September 2015 (in Swedish).

[7] "Bioinvent i nytt cancer–samarbete", Dagens Nyheter, 4 January 2012 (in Swedish; subscription required).

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Revision as of 05:51, 16 August 2019 edit BigDwiki (talk \| contribs) Extended confirmed users 25,474 edits m →‎top: Minor Clean Up and Fixes, added orphan tag Tag: AWB ← Previous edit		Revision as of 14:30, 27 August 2019 edit undo Ljuvlig (talk \| contribs) 57 edits m 1 link added Next edit →
Line 1:		Line 1:
	{{Orphan\|date=August 2019}}

	'''BioInvent International''' is a Swedish research, pharmaceutical and life science company with focus on clinical development of antibody drugs for [[immunotherapy]] against [[cancer]].<ref>Maria Phillips, [https://www.di.se/live/bioinvent-rasar-efter-emissionsbesked/ "Bioinvent rasar efter emissionsbesked"], ''Dagens industri'', 25 February 2019 (in Swedish).</ref> The company was founded in 1983 by {{interlanguage link\|Carl Borrebaeck\|sv}} and is listed on the [[Stockholm Stock Exchange]] since 2001. The company's partners include [[Bayer HealthCare]], [[Daiichi Sankyo]], Mitsubishi Tanabe and [[Servier]]. Martin Welschof has been CEO since 2018.<ref>[https://news.cision.com/se/bioinvent/r/bioinvent-rekryterar-martin-welschof-som-ny-vd,c2493851 "BioInvent rekryterar Martin Welschof som ny vd"] (press release), Cision, 12 April 2018 (in Swedish).</ref><ref>[https://www.avanza.se/aktier/om-aktien.html/5505/bioinvent-international "BioInvent International"], Avanza Bank, retrieved 19 June 2019 (in Swedish).</ref><ref>[http://www.bioinvent.com/technology/ "Technology"], Bioinvent, retrieved 19 June 2019.</ref><ref>Kajsa-Stina Kalin, [https://www.sydsvenskan.se/2013-10-04/bioinvent-var-pionjarer-i-parken "Bioinvent var pionjärer i parken"] ''Sydsvenskan'', 4 October 2015 (in Swedish).</ref><ref>Maria Lindh, [http://www.lum.lu.se/forskningen-som-ledde-till-miljardavtalet/ "Forskningen som ledde till miljardavtalet"], ''LUM.'', Lund University, 11 September 2015 (in Swedish).</ref><ref>[https://www.dn.se/ekonomi/bioinvent-i-nytt-cancersamarbete/ "Bioinvent i nytt cancer–samarbete"], ''Dagens Nyheter'', 4 January 2012 (in Swedish; subscription required).</ref>		'''BioInvent International''' is a Swedish research, pharmaceutical and life science company with focus on clinical development of antibody drugs for [[immunotherapy]] against [[cancer]].<ref>Maria Phillips, [https://www.di.se/live/bioinvent-rasar-efter-emissionsbesked/ "Bioinvent rasar efter emissionsbesked"], ''Dagens industri'', 25 February 2019 (in Swedish).</ref> The company was founded in 1983 by {{interlanguage link\|Carl Borrebaeck\|sv}} and is listed on the [[Stockholm Stock Exchange]] since 2001. The company's partners include [[Bayer HealthCare]], [[Daiichi Sankyo]], Mitsubishi Tanabe and [[Servier]]. Martin Welschof has been CEO since 2018.<ref>[https://news.cision.com/se/bioinvent/r/bioinvent-rekryterar-martin-welschof-som-ny-vd,c2493851 "BioInvent rekryterar Martin Welschof som ny vd"] (press release), Cision, 12 April 2018 (in Swedish).</ref><ref>[https://www.avanza.se/aktier/om-aktien.html/5505/bioinvent-international "BioInvent International"], Avanza Bank, retrieved 19 June 2019 (in Swedish).</ref><ref>[http://www.bioinvent.com/technology/ "Technology"], Bioinvent, retrieved 19 June 2019.</ref><ref>Kajsa-Stina Kalin, [https://www.sydsvenskan.se/2013-10-04/bioinvent-var-pionjarer-i-parken "Bioinvent var pionjärer i parken"] ''Sydsvenskan'', 4 October 2015 (in Swedish).</ref><ref>Maria Lindh, [http://www.lum.lu.se/forskningen-som-ledde-till-miljardavtalet/ "Forskningen som ledde till miljardavtalet"], ''LUM.'', Lund University, 11 September 2015 (in Swedish).</ref><ref>[https://www.dn.se/ekonomi/bioinvent-i-nytt-cancersamarbete/ "Bioinvent i nytt cancer–samarbete"], ''Dagens Nyheter'', 4 January 2012 (in Swedish; subscription required).</ref>